Key result
In individuals at low risk for cardiovascular disease, aspirin reduces the risk of myocardial infarction at the cost of an increase in major bleeding, with a modest reduction in total mortality.
Why the study?
Does aspirin provide a net benefit for the primary prevention of cardiovascular disease in individuals at low risk?
Does aspirin provide a net benefit for the primary prevention of cardiovascular disease in individuals at low risk?
Aspirin for primary prevention in low-risk individuals reduces MI but increases major bleeding, highlighting the need for individualized shared decision-making.
No takes yet. Share an insight, caveat, or question.
Reinforces individualized shared decision-making in low-risk primary prevention; leaves open refined risk thresholds in updated trials.
Raju et al. (2012) conducted a review in Primary prevention of cardiovascular disease (n=102,621). Aspirin vs. Placebo or no aspirin was evaluated on Cardiovascular events, mortality, and major bleeding. In individuals at low risk for cardiovascular disease, aspirin reduces the risk of myocardial infarction at the cost of an increase in major bleeding, with a modest reduction in total mortality.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: